Research of targeted therapy for renal cancer from 2006 to 2022: a bibliometric and visualized analysis
Targeted therapy for renal cancer is a rapidly expanding research area, with emerging hotspots in immune checkpoint inhibition and hypoxia‑related pathways.
Background: This review aimed to analyze the research progress and development trends in targeted therapy (TT) for renal cancer (RC) from 2006 to 2022. Methods: The Web of Science Core Collection database was searched using the search terms “renal cancer”, “kidney neoplasms”, “kidney cancer”, and “targeted therapy”, and all publications were extracted. VOSviewer version 1.6.18 was used to perform visual analysis. Results: A total of 1,136 studies related to TT for RC were found. The top journals were the Journal of Clinical Oncology, Annals of Oncology, and European Urology. The United States led the contributions (366 articles). The main document type was article (64.26%). Conclusions: This is the first bibliometric analysis related to TT for RC. Publication numbers have steadily increased, driven mainly by the United States. Key research hotspots include hypoxia‑inducible factor‑1, drug resistance, and therapeutic targets. Keywords: Targeted therapy, renal cancer, bibliometric analysis, VOSviewer
The bibliometric overview identifies prevailing research trends and informs researchers and clinicians where to focus future studies, thus accelerating discovery of effective targeted treatments for renal cancer.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells